

ADVENTRX PHARMACEUTICALS INC

Form 8-K

January 14, 2008

**Table of Contents**

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
FORM 8-K  
CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934  
Date of report (Date of earliest event reported): **January 14, 2008**  
**ADVENTRX Pharmaceuticals, Inc.**  
(Exact Name of Registrant as Specified in Charter)**

**Delaware**  
(State or Other Jurisdiction of  
Incorporation)

**001-32157**  
(Commission File No.)

**84-1318182**  
(IRS Employer Identification No.)

**6725 Mesa Ridge Road, Suite 100**  
**San Diego, CA 92121**  
(Address of Principal Executive Offices and Zip Code)  
**N/A**

(Former name or former address if changed since last report)

Registrant's telephone number, including area code: **(858) 552-0866**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**TABLE OF CONTENTS**

Item 8.01. Other Events.

Item 9.01. Financial Statements and Exhibits.

SIGNATURE

INDEX TO EXHIBITS

EXHIBIT 99.1

---

**Table of Contents**

**Item 8.01. Other Events.**

On January 14, 2008, ADVENTRX Pharmaceuticals, Inc. ( ADVENTRX ) updated aspects of its corporate presentation as reflected in the slides attached as Exhibit 99.1 to this Current Report on Form 8-K (the Report ), which slides are incorporated herein by reference. Evan M. Levine, Chief Executive Officer of ADVENTRX, and other ADVENTRX executives will present the information reflected in the slides attached as Exhibit 99.1 to this Report commencing January 14, 2008 at various investor and analyst meetings.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

The list of exhibits called for by this Item is incorporated by reference to the Index to Exhibits filed with this report.

**Forward Looking Statements**

ADVENTRX cautions you that statements information included in the slides attached hereto as Exhibit 99.1 that are not a description of historical facts are forward-looking statements that involve risks and assumptions that, if they materialize or do not prove to be accurate, could cause ADVENTRX s results to differ materially from historical results or those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that ADVENTRX will be unable to raise sufficient capital to fund the projects necessary to meet its anticipated or stated goals and milestones; the risk that preclinical results are not indicative of the success of subsequent clinical trials and the results of pending clinical trials; the risk the FDA determines ADVENTRX s product candidates are not bioequivalent to the applicable reference product; difficulties or delays in manufacturing, marketing and obtaining regulatory approval for ADVENTRX s product candidates; the potential for regulatory authorities to require additional preclinical work or other clinical requirements to support regulatory filings; the scope and validity of patent protection for ADVENTRX s product candidates; patent and non-patent exclusivity covering Navelbin® and Taxotere®; and other risks and uncertainties more fully described in ADVENTRX s press releases and periodic filings with the Securities and Exchange Commission. ADVENTRX s public filings with the Securities and Exchange Commission are available at <http://www.sec.gov>.

You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date when made. ADVENTRX does not intend to update any forward-looking statement included in the slides attached hereto as Exhibit 99.1 to reflect events or circumstances arising after the date on which it was made. This caution is made under the safe harbor provisions of Section 21E of the Securities Exchange Act of 1934.

---

**Table of Contents**

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

**ADVENTRX Pharmaceuticals, Inc.**

Dated: January 14, 2008

By: /s/ Evan M. Levine

Name: Evan M. Levine

Title: Chief Executive Officer

---

**Table of Contents**

INDEX TO EXHIBITS

99.1 Presentation slides